Research Summary

Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression

Authors 

Nolan R. Williams, M.D., Eleanor J. Cole, Ph.D., Brandon S. Bentzley, M.D., Ph.D., et al.

Key Takeaways

• Remission: 90.5% of participants (19 out of 21) met the criteria for remission (MADRS score ≤10) following the treatment protocol.
• Average Time to Remission: On average, participants achieved the remission criterion (6-item HAM-D score <5) after 2.63 days of treatment
• Duration: The protocol was administered over a 5-day window. 
• Safety: The treatment was well tolerated, with no serious adverse events. Reported side effects were mild (e.g., fatigue and localized discomfort).
• Cognitive Impact: Neuropsychological testing showed no evidence of post-treatment cognitive impairment or memory decline.
• Targeting: The protocol employed personalized functional MRI (fMRI) to determine individual stimulation coordinates.

What This Means for SAINT 

This open-label study was an initial evaluation of the safety, feasibility, and efficacy of Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). The study sought to determine if combining high-dose intermittent theta-burst stimulation (iTBS) with an accelerated schedule and personalized fMRI targeting could reduce symptom severity in patients with treatment-resistant depression (TRD).

1. Accelerated iTBS Protocol Feasibility 

The study used a compressed schedule of 10 iTBS sessions per day, with 50-minute inter-session intervals, for 5 consecutive days. This delivery method provided a total dose of 90,000 pulses—significantly higher than the 18,000 to 30,000 pulses typically delivered over 6 weeks in standard FDA-cleared TMS protocols. The data suggests that this high-dose, accelerated schedule works in a clinical setting.

2. Individualized fMRI-Guided Targeting 

Unlike standard TMS, which uses external landmarks or structural MRI for positioning, the SAINT protocol used fMRI to identify a specific subregion of the left dorsolateral prefrontal cortex (dlPFC). This approach was designed to address individual differences in brain architecture.

3. Application of Spaced Learning Theory 

The protocol’s timing—specifically the 50-minute break between sessions—is based on the neurobiological principle of spaced learning. This interval is hypothesized to optimize the induction of long-term potentiation (LTP) and enhance the strengthening of neural connections. The high remission rates observed suggest that this temporal spacing may be relevant to the clinical efficacy of the stimulation.

4. Outcomes for High-Resistance Populations 

Participants in this study had a high level of treatment resistance, with an average of 5.2 failed medication trials in their current episode. The results demonstrate that an intensive, targeted neuromodulation approach can elicit a clinical response even in patients who have not responded to multiple conventional therapies.

Expert Perspective 

“SAINT produced ultra-rapid, near-universal remission—even among prior rTMS nonresponders—with meaningful clinical improvement emerging in just two and a half days and complete resolution of suicidality post-treatment. These findings signal a step-change in both the speed and scope of antidepressant response, extending efficacy to patients historically considered refractory.” – Brandon Bentzley, MD, PhD

Study Overview and Methodology 

This prospective, open-label, single-arm study was designed to evaluate the safety and efficacy of the SAINT protocol in participants diagnosed with moderate-to-severe treatment-resistant depression (TRD). On average, participants had been in their current depressive episode for 7.9 years and had failed multiple antidepressant medications prior to enrollment.

The treatment protocol consisted of 50 sessions administered over a five-day period. The primary measurable endpoint was the change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores from the baseline to the conclusion of the five-day treatment window. To ensure participant safety, cognitive and neuropsychological assessments were administered both before and after the intervention to monitor for potential adverse effects on memory or executive function.

Key Findings

• Remission and Response: 90.5% of participants achieved remission at the primary endpoint. 
• Symptom Reduction: The average MADRS score decreased from 35.2 at baseline to 10.2 following the 5-day treatment.
• Safety and Tolerability: No serious adverse events occurred. The most common side effects were fatigue and scalp discomfort during stimulation. 
• Dose-Response Relationship: The study suggests that the higher cumulative dose and individualized targeting may contribute to the significant clinical improvement.

Frequently Asked Questions

1. Is the high dose of stimulation safe for the patient? The study found that the SAINT protocol, which delivers higher daily and total doses than standard TMS, was safe and well tolerated. Systematic cognitive testing indicated no adverse impact on memory or cognitive processing speed.

2. How long do the effects of this 5-day treatment last? In this open-label study, follow-up data showed that significant improvements were maintained for many participants, though the duration of the effect varied. Further research, including randomized controlled trials, is necessary to establish the long-term durability of the response.

3. How is the targeting process performed? The process begins with an fMRI scan to map the patient’s unique brain connectivity. Software is used to identify the area of the dlPFC that is most strongly anticorrelated with the sgACC. This individualized coordinate is then used to position the TMS coil for all 50 treatment sessions.

Citation & Original Source

Cole, E. J., et al. (2020). Stanford Accelerated Intelligent Neuromodulation Therapy for treatment-resistant depression. The American Journal of Psychiatry, 177(8), 716–726. https://doi.org/10.1176/appi.ajp.2019.19070720

Read the Full Study Here: The American Journal of Psychiatry